risperidone (Perseris)

Long-acting injectable antipsychotic • Brands: PERSERIS

Last reviewed: 2025-12-30

General information

Class: Long-acting injectable antipsychotic
Common US brands: PERSERIS
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Monthly subcutaneous long-acting risperidone depot (D2/5-HT2A antagonist) intended for schizophrenia maintenance when scheduled injection visits support adherence.

Metabolism & Half‑life

Metabolism: CYP2D6
Half‑life: Single-dose range 216–264 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Long‑acting injectable (LAI)

Risperidone (Perseris)

Interval: Monthly (q4wk)
Oral overlap: None after first injection (establish oral tolerability first)
Site: Subcutaneous (abdomen or back of arm)

Citations

Label PMID

Monitoring highlights

Sources

PERSERIS (risperidone) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
RISPERDAL (risperidone) prescribing information — DailyMed (2025)
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis — The Lancet (2013)
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsycharmacology — Pharmacopsychiatry (2018)